An evaluation of emerging vaccines for childhood pneumococcal pneumonia

Webster, Julia; Theodoratou, Evropi; Nair, Harish; Seong, Ang Choon; Zgaga, Lina; Huda, Tanvir; Johnson, Hope L.; Madhi, Shabir; Rubens, Craig; Zhang, Jian Shayne F.; Arifeen, Shams El; Krause, Ryoko; Jacobs, Troy A.; Brooks, Abdullah W.; Campbell, Harry; Rudan, Igor
January 2011
BMC Public Health;2011 Supplement 3, Vol. 11 Issue Suppl 3, p1
Academic Journal
Background: Pneumonia is the leading cause of child mortality worldwide. Streptococcus pneumoniae (SP) or pneumococcus is estimated to cause 821,000 child deaths each year. It has over 90 serotypes, of which 7 to 13 serotypes are included in current formulations of pneumococcal conjugate vaccines that are efficacious in young children. To further reduce the burden from SP pneumonia, a vaccine is required that could protect children from a greater diversity of serotypes. Two different types of vaccines against pneumococcal pneumonia are currently at varying stages of development: a multivalent pneumococcal conjugate vaccine covering additional SP serotypes; and a conserved common pneumococcal protein antigen (PPA) vaccine offering protection for all serotypes. Methods: We used a modified CHNRI methodology for setting priorities in health research investments. This was done in two stages. In Stage I, we systematically reviewed the literature related to emerging SP vaccines relevant to several criteria of interest: answerability; efficacy and effectiveness; cost of development, production and implementation; deliverability, affordability and sustainability; maximum potential for disease burden reduction; acceptability to the end users and health workers; and effect on equity. In Stage II, we conducted an expert opinion exercise by inviting 20 experts (leading basic scientists, international public health researchers, international policy makers and representatives of pharmaceutical companies). The policy makers and industry representatives accepted our invitation on the condition of anonymity, due to sensitive nature of their involvement in such exercises. They answered questions from CHNRI framework and their "collective optimism" towards each criterion was documented on a scale from 0 to 100%. Results: The experts expressed very high level of optimism (over 80%) that low-cost polysaccharide conjugate SP vaccines would satisfy each of the 9 relevant CHNRI criteria. The median potential effectiveness of conjugate SP vaccines in reduction of overall childhood pneumonia mortality was predicted to be about 25% (interquartile range 20-38%, min. 15%, max 45%). For low cost, cross-protective common protein vaccines for SP the experts expressed concerns over answerability (72%) and the level of development costs (50%), while the scores for all other criteria were over 80%. The median potential effectiveness of common protein vaccines in reduction of overall childhood pneumonia mortality was predicted to be about 30% (interquartile range 26-40%, min. 20%, max 45%). Conclusions: Improved SP vaccines are a very promising investment that could substantially contribute to reduction of child mortality world-wide.


Related Articles

  • Infants too young to receive pneumococcal conjugate vaccine benefit from herd immunity. Carter, R. J. F. // Thorax;Jul2006, Vol. 61 Issue 7, p610 

    The article reports that infants too young to receive a heptavalent pneumococcal conjugate vaccine (PCV7) are benefiting from herd immunity. Evidence has shown that the rate of invasive pneumococcal disease (IPD) among children younger than 2 years has reduced since the introduction of PCV7....

  • Population-Based Results for Pneumococcal Conjugate Vaccine. Zepf, Bill // American Family Physician;1/1/2004, Vol. 69 Issue 1, p193 

    Presents a study which examined the impact of the introduction of protein-polysaccharide conjugate vaccine in reducing the incidence of invasive pneumococcal disease in young children. Analysis of data; Baseline rate of invasive pneumococcal disease among children younger than two years;...

  • Appropriateness of a Pneumococcal Conjugate Vaccine in Brazil: Potential Impact of Age and Clinical Diagnosis, with Emphasis on Meningitis. Brandileone, Maria-Cristina C.; Sgambatti de Andrade, Ana-Lucia S.; Di Fabio, José-Luis; Guerra, Maria-Luiza L.S.; Austrian, Robert // Journal of Infectious Diseases;4/15/2003, Vol. 187 Issue 8, p1206 

    Analyzes the distribution of pneumococcal serotypes in Brazil by age group and clinical diagnosis, using data obtained during 20 years of national surveillance. Indication that serotypes 1 and 5 are among the main serotypes in all age groups; Finding that the use of conjugate vaccine may be of...

  • Briefly... Asnes, Marion // Money;Oct2003, Vol. 32 Issue 10, p37 

    On top of diapers and bottles, new parents are faced with a long list of vaccines to get for their kids.The latest, Prevnar, protects against some types of meningitis and pneumonia, as well as some ear infections.It's costly-- $200 to $300 for the series--and some health plans don't cover...

  • Global measles elimination. Moss, William J.; Griffin, Diane E. // Nature Reviews Microbiology;Dec2006, Vol. 4 Issue 12, p900 

    Measles remains a leading vaccine-preventable cause of child mortality worldwide, particularly in sub-Saharan Africa where almost half of the estimated 454,000 measles deaths in 2004 occurred. However, great progress in measles control has been made in resource-poor countries through accelerated...

  • Vexing Vaccines. Bowman, Darcia Harris // Education Week;7/28/2004, Vol. 23 Issue 43, p26 

    When whooping cough first turned up in Westchester County, New York, a year ago, it wasn't necessarily noteworthy. True, the contagious bacterial infection was once a major cause of death among infants and young children in the U.S. But that was before widespread immunization, and Westchester...

  • Ten Great Public Health Achievements -- Worldwide, 2001-2010. Koppaka, Ram // MMWR: Morbidity & Mortality Weekly Report;6/24/2011, Vol. 60 Issue 24, p814 

    The article discusses the 10 great public health achievements from around the world from 2001 to 2010. One of the key achievements of health agencies worldwide was the reduction in child mortality. Aside from this, they also succeeded in terms of preventing some diseases like polio and measles...

  • Understanding S. Pneumoniae. Corry, Margarita; Whelan, Jacqueline // World of Irish Nursing & Midwifery;Sep2006, Vol. 14 Issue 8, p55 

    The article discusses the nature of streptococcus pneumonia also known as the pneumococcal pneumonia, a potentially vaccine-preventable disease which is among the leading causes of illness and death in young children worldwide. The disease is caused by an anaerobic gram positive bacterium. It is...

  • Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate Vaccine. Pilishvili, Tamara; Lexau, Catherine; Farley, Monica M.; Hadler, James; Harrison, Lee H.; Bennett, Nancy M.; Reingold, Arthur; Thomas, Ann; Schaffner, William; Craig, Allen S.; Smith, Philip J.; Beall, Bernard W.; Whitney, Cynthia G.; Moore, Matthew R. // Journal of Infectious Diseases;1/1/2010, Vol. 201 Issue 1, p32 

    Background. Changes in invasive pneumococcal disease (IPD) incidence were evaluated after 7 years of 7-valent pneumococcal conjugate vaccine (PCV7) use in US children. Methods. Laboratory-confirmed IPD cases were identified during 1998-2007 by 8 active population-based surveillance sites. We...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics